Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin

Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Areas of Uncertainty: Despite initial concerns that psilocybin could cause long-lasting mental health problems such as psychosis, contemporary research has demonstrated that psilocybin is psychologically and physiologically safe. Adverse psychiatric outcomes can generally be avoided in controlled settings such as clinical trials. However, considerations regarding optimal dosing, therapeutic protocols, and integration strategies for psychedelic experiences remain imperative for the responsible clinical implementation of psilocybin-assisted therapy. Therapeutic Advances: In clinical trials, psilocybin has shown promise for treating major depressive disorder and treatment-resistant depression. Initial studies indicated that 42-57% of patients underwent remission after psilocybin-assisted therapy, which suggests that psilocybin is more effective than existing antidepressant medications. However, larger Phase II trials with more than 100 participants have shown a much smaller remission rate of 25-29%, though these studies still observed that psilocybin causes a significant reduction in depressive symptoms. Clinical data has also demonstrated that psilocybin can manage substance use disorders and end-of-life anxiety. Conclusion: Psilocybin is the most clinically well-researched psychedelic drug, with trials that have enrolled hundreds of participants and therapeutic applications that span multiple psychiatric conditions. Phase III trials, which have already commenced, will determine whether psilocybin lives up to the promise that it showed in previous clinical trials.